126714-65-6

Basic information

• Product Name: (4-bromophenyl)(methoxymethyl)sulfane
• Synonyms: (4-bromophenyl)(methoxymethyl)sulfane
• CAS NO: 126714-65-6
• Molecular Weight: 233.129
• Mol File: 126714-65-6.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: (4-bromophenyl)(methoxymethyl)sulfane(CAS DataBase Reference)
• NIST Chemistry Reference: (4-bromophenyl)(methoxymethyl)sulfane(126714-65-6)
• EPA Substance Registry System: (4-bromophenyl)(methoxymethyl)sulfane(126714-65-6)

Safety Data

• Hazardous Substances Data: 126714-65-6(Hazardous Substances Data)

Upstream product

• 109-87-5 Dimethoxymethane 
• 106-53-6 para-bromobenzenethiol 
• 105-36-2 ethyl bromoacetate 
• 75-36-5 acetyl chloride 
• 107-30-2 chloromethyl methyl ether 

Downstream Products

• 126714-68-9 methoxy(4-carboxyphenylthio)methane 
• 1021169-69-6 1-bromo-4-(methoxymethylsulfonyl)benzene 
• 1072952-17-0 4-(methoxymethylthio)phenylboronic acid 
• 126714-75-8 methoxy(4-methoxymethylselenophenylthio)methane 
• 126714-76-9 methoxy(4-methoxymethylthiophenylthio)methane 
• 98-58-8 4-bromobenzenesulfonyl chloride 
• 146335-13-9 2-Fluoro-1-(4-methoxymethylsulfanyl-phenyl)-ethanone 

Relevant articles and documents

SSAO INHIBITORS AND USE THEREOF

Provided are a compound of formula (I') or (I), a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, or tautomer thereof, which modulates the activity of SSAO, a pharmaceutical composition comprising a compound of formula (I') or (I), and a method of treating or preventing a disease in which SSAO plays a role.

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.